Smimmary Intracranial germinoma has usually been treated with radiation doses of 50 Gy or more, but it is unclear whether such doses are actually necessary to cure this radiosensitive tumour. At our institution, the standard radiation dose for intracranial germinoma was 60 Gy in the 1960s, but the dose has prospectively been reduced stepwise to 40-45 Gy. In this paper. the treatment outcome was assessed in 84 patients (47 with histologically confirmed disease and 37 diagnosed clinically in the post-computerised tomography era) enrolled in both prospective and retrospective series. The 5 and 10 year survival rates for all 84 patients were 88% and 83% respectively, and the corresponding relapse-free survival rates were 88% and 85%. The 10-year relapsefree survival rate was 88% for 31 patients receiving 19-47 Gy (median 42 Gy) to the primary tumour. 92% for 28 patients receiving 48-52 Gy (median 50 Gy), and 83% for 25 patients receiving 54-62 Gy (median 60 Gy). and there was no significant difference among the three groups. In-field local recurrence only developed in one patient who received 40 Gy over a protracted period and one patient who received 60 Gy. A tumour size <3 cm and treatment in the post-computerised tomography era were associated with a better prognosis according to univariate analysis, while age, sex, tumour site, treatment volume, the radiation dose to both the primary and the spinal cord and the extent of surgical resection did not influence the prognosis. In contrast, none of these factors had a significant influence in multivanrate analysis. In conclusion, intracranial germinomas _ 4 cm in size can usually be cured with 40-45 Gy of radiation, thus avoiding the major adverse effects of brain irradiation.
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Intracranial germinoma is the most radiosensitive of the pnmary intracranial neoplasms and its standard treatment is radiation therapy. A radiation dose of 50Gy is most commonly given to the primary tumour, resulting in a cure rate of 70-95% (Sung et al.. 1978; Wara et al., 1979; Lindstadt et al., 1988; Dearnaley et at.. 1990 ). This dose of 50 Gy was chosen empirically on the basis of the fact that it is usually safe for normal brain tissue. However, there is some question as to whether as much radiation as 50 Gy is really necessary to cure this radiosensitive tumour, since testicular seminoma (which is histologically identical to intracranial germinoma) can be treated successfully with 25-35 Gy of radiation (Thomas & Williams. 1992) . This important issue has not been addressed systematically in a clinical trial, probably because of the relative rarity of germinoma and the fear of increased recurrence following dose reduction.
At our hospital, the radiation dose used to treat intracranial germinoma has been prospectively reduced over the past 20 years. A dose of 60 Gy was commonly used in the 1960s. at which time the disease was not so well understood, but the dose was reduced to 50 Gy in the 1970s after recognition of its high radiosensitivity. After the late 1970s, some patients were given even lower doses of 40-45 Gy as a pilot study, and these lower doses have become standard since 1985 (except for patients with very large tumours). This paper reports the results of our dose reduction study for intracranial germinoma, together with the long-term outcome in the patients previously given higher doses.
Patients and methods

Subjects
Eighty-four patients with intracranial germinoma who received radiation therapy at our hospitals between January 1963 and December 1992 were eligible for this study. There were 66 males and 18 females aged from 6 to 44 years. with a median age of 15 years. The primary tumour site was the pineal region in 30, the suprasellar/sellar region (including the anterior part of the third ventricle) in 37, both the pineal and suprasellar regions in nine, and the basal ganglia or thalamus in eight. Forty-seven patients had histological confirmation of the diagnosis, while the remaining 37 patients were diagnosed on the basis of clinical criteria (Spiegel et al., 1976; Bloom, 1983; Shibamoto et al., 1994) including a typical age, tumour site, typical computerised tomography (CT) and/or magnetic resonance imaging (MRI) findings, and a rapid response to radiation therapy. Twentyone of these 37 patients also had positive cerebrospinal fluid (CSF) cytology findings in which large and round germinoma cells were observed against a background of lymphocytes (Shibamoto et al., 1994) . Another 20 patients were treated for suspected germinoma in the pre-CT era, but they were not included in this analysis because of the relative uncertainty of the diagnosis. One patient who died during the early stage of radiotherapy was also excluded.
It is the policy at our institutions (and also at most other Japanese institutions) not Months not shown). Also, survival and relapse-free survival did not vary significantly depending on the treatment volume ( Figure  4 ) and the dose to the spinal axis (Table I) . Table I ).
Fugwe 4 Relapse-free survival according to the treatment volume. The differens between the four groups were not sipificant (P-alues are given in Table I ). (Kraichoke et al., 1988) . Since the lesion had been resected totally, no further postoperative irradiation was given.
As a radiation sequela, brain necrosis developed in one patient (no. 1 in Table II ) who received irradiation twice as described previously (Shibamoto et al., 1988 (Duffner et al., 1985) . Therefore, it seems quite important to investigate the possibility of dose reduction. There have been a few previous reports on the successful treatment of patients with intracranial germinoma using doses of 45 Gy or less (Sung et al., 1978; Amendola et al., 1984; Fields et al., 1987; Jenkin et al., 1990) . However, the numbers have been small and the follow-up period insufficient in most reports, so that no firm conclusions could be drawn. It is noteworthy, however, that a few patients have been successfully treated with very low doses. The relatively old literature reports two patients who are alive at 25 years and 18 years after receiving 1,800 R and 2,950 R of radiation respectively (Simson et al., 1968; Camins & Mount, 1974) . Recently, Aydin et al. (1992) reported on a patient with biopsy-proven germinoma who died accidentally after receiving 16 Gy of irradiation. At autopsy, no viable tumour cells were found and the authors suggested that this disease could possibly be cured by much lower doses than those currently used. Also in our series, one patient who only received 19.5Gy is still recurrece free at 15 years.
On the other hand, we found in-field local recurrence mn one patient who had a poor gnral condition and received 40 Gy in 27 fractions given over 49 days. Because of the protracted delivery of the radiation, this did not correspond to the current practice of delivering 40 Gy in 20-24 fractions over 4-5 weeks. The literature also records many patients who developed local recurrence after doses of 30-60 Gy (Simson et al., 1968; Sung et al., 1978; Amendola et al., 1984) . Since the radiation procedure is not necessarily described in detail, it is generally unclear from these reports whether local recurr was due to underdosage or not. Some patients may still develop local recurrence even after 50 Gy of irradiation and we had one patient who developed recurrence 9 years after receiving a dose of 60 Gy. In a recent review, Fuller et al. (1994) found no correlation between the radiation dose and disease-free survival or overall survival. Our results also indicated that the prognosis is not different between patients receiving 40-45 Gy and 50 Gy or more. However, the toxicity of these lower doses appears to be less than that of radiation doses > 50 Gy. Therefore, it seems reasonable for the standard radiation dose to be reduced to 40-45 Gy for germinomas klss than 4cm in diameter. The next challenge may be to investigate the possibility of furher dose reduction.
With regard to prophylactic craniospinal irradiation, the optimum dose is still unclear. CSF dissemination occurred in one of our patients who had positive cytology and intraventricular dissemination at presentation and received 23.7 Gy to the cranospinal axis. On the other hand, seven patients who had positive CSF cytology and received 20 Gy or less to the craniospinal axis are currently doing well 2-15 years after therapy. Thus, we will continue to investigate whether 20 Gy is an appropriate dose or not.
Systemic chemotherapy using cisplatin and etoposide is presently being investigated for germinoma in some institutions (Patel et al., 1992; Yoshida et al., 1993) . The rationale for performing chemotherapy is that radiation can have adverse effects on the normal brain while chemotherapy does not. However, it has become clear that chemotherapy is associated with an unacceptably high recurrence rate (Yoshida et al., 1993; Shibamoto et al., 1994) and the longterm toxicity (particuarly on the genital organs) is still unclear. Our study showed that intracranial germinoma can be cured with lower radiation doses than have been standard, thus eliminating the major adverse effects of radiation in adolescents and adults. Therefore, chemotherapy (in combination with even lower dose irradiation) may only be worth consideration for children in whom 40 Gy of irradiation might still have unfavourable effects and for recurrent cases.
Regarding the treatment volume, we are using an individualised approach. According to the rview by Brada & Rajan (1990) , the incidence of spinal seeding in intracranial germinoma was 13% following brain irradiation alone. This rate may be too low to justify the routine use of craniospinal irradiation, but is also not negligible. We recently found that patients with positive CSF cytology have a higher risk of CSF dissemination (Shibamoto et al., 1994) 
